Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.

@article{Seto2013ReductionOH,
  title={Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.},
  author={Wai-Kay Seto and Danny Ka-ho Wong and James Fung and Fung-yu Huang and Ching-lung Lai and M. Josephine Yuen},
  journal={Hepatology},
  year={2013},
  volume={58 3},
  pages={
          923-31
        }
}
UNLABELLED The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our center. Patients were recruited if they were continuously treated with lamivudine for at least 10 years and maintained favorable virologic responses throughout therapy (HBV DNA <2,000 IU/mL). HBsAg and HBV DNA levels were… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 6 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B

  • P Lampertico, M Vigano, C Cheroni, F Facchetti, F Invernizzi, V Valveri
  • HEPATOLOGY
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…